Northpointe Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Northpointe Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-98,329	Closed	-$912K	–	205
2017 Q4	$912K	Sell	98,329 -4,618	-4%	-$46.4K	0.1%	163
2017 Q3	$1.2M	Sell	102,947 -64,061	-38%	-$2.43M	0.13%	162
2017 Q2	$6.97M	Buy	167,008 +14,672	+10%	+$706K	0.73%	50
2017 Q1	$7.42M	Sell	152,336 -22,136	-13%	-$865K	0.81%	40
2016 Q4	$5.75M	Sell	174,472 -5,314	-3%	-$175K	0.57%	63
2016 Q3	$7.36M	Buy	179,786 +85,284	+90%	+$3.35M	0.76%	44
2016 Q2	$3.1M	Sell	94,502 -25,201	-21%	-$924K	0.37%	95
2016 Q1	$7.41M	Buy	119,703 +69,727	+140%	+$2.21M	0.92%	30
2015 Q4	$2.74M	Hold	49,976	–	–	0.36%	107
2015 Q3	$2.74M	Buy	+49,976	New	+$4.96M	0.36%	108

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northpointe Capital's GNCA Position: Q1 2018 in Review

Northpointe Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2018, closing a stake of 98,329 shares — an estimated $912K sold.

Northpointe Capital first reported a position in GNCA in Q3 2015 and held it in 10 quarters. The position peaked at $7.42M in Q1 2017. 65 funds tracked by Wall St. Rank hold GNCA as of Q1 2018.

Northpointe Capital reported no remaining Genocea Biosciences, Inc. position as of Q1 2018 after selling out during the quarter.
Northpointe Capital sold 98,329 Genocea Biosciences, Inc. shares in Q1 2018, an estimated $912K.
Northpointe Capital first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 10 quarters.
Northpointe Capital's Genocea Biosciences, Inc. position peaked at $7.42M in Q1 2017.
65 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2018.

Based on Northpointe Capital's 13F filing for Q1 2018, filed 11 Apr 2018.